Healthcare providers notice that semaglutide is effective in controlling blood sugar and aiding weight loss
The following table describes GLP-1 receptor agonists, their dosing frequency and key pharmacokinetic parameters: Cautions and Contraindications Adverse Effects Acute pancreatitis (rare) Injection site reactions Gastrointestinal disturbances (nausea, vomiting, diarrhoea dehydration and possible renal impairment) Increase in pancreatic enzymes: lipase and amylase (dulaglutide, tirzepatide and semaglutide) Cholecystitis and cholelithiasis Delayed gastric emptying (semaglutide, exenatide, dulaglutide, tirzepatide (diminishes over time)) Increased heart rate Diabetic retinopathy complications (semaglutide, particularly in insulin-treated patients with known diabetic retinopathy) Interactions GLP-1 receptor agonists do not interact via cytochrome P450 , but delayed gastric emptying may alter drug absorption
That is your injection day
It should be noted that only semaglutide injection (not oral) was compared to tirzepatide, and higher doses of semaglutide were not compared to tirzeparatide.[21] The mean A1c reduction from baseline was above 2% and weight reduction was near 10 kg (22 lbs) in tirzepatide clinical studies, exceeding current FDA-approved GLP-1 products
However, a study published in the New England Journal of Medicine found that patients treated with Ozempic experienced significant weight loss, averaging 15% of their body weight over 68 weeks